The bill proposes the enactment of section 3902.65 of the Revised Code, which aims to cap the cost-sharing amount for prescription insulin drugs. It defines a "prescription insulin drug" as any prescription medication containing insulin used for diabetes treatment. The bill stipulates that health plan issuers providing coverage for these drugs cannot require cost sharing that exceeds thirty-five dollars for a thirty-day supply, regardless of the type or amount of insulin prescribed.

This new regulation will apply to health benefit plans that are amended, issued, or renewed on or after the effective date of the bill. The cost-sharing limit is intended to alleviate the financial burden on individuals requiring insulin, ensuring that they can access necessary medications without excessive out-of-pocket expenses.